HK Stock Market Move | Joinn Laboratories (06127) rises over 5% against the trend; institutions are bullish on the company's medium- to long-term business growth potential.

Joinn Laboratories (06127) rose over 5% against the trend, up 5.02% as of press time, at HK$30.98, with a turnover of HK$204 million. On the news front, the 2026 Nobel Prize in Physiology or Medicine was awarded in the field of optogenetics, marking the official transition of this foundational biotechnology from basic research to industrial application. Public information shows that Joinn Laboratories, on the one hand, indirectly holds a stake in Jianda Jiuzhou through the Beinao Phase I Fund, deeply binding itself to the optogenetics pipeline; on the other hand, it possesses non-clinical safety evaluation CRO capabilities and a non-human primate animal model platform, enabling it to undertake toxicology testing and circuit validation evaluation business for central nervous system new drugs following the localization of neural circuits through optogenetics technology. Huatai previously noted that the company's total order backlog in hand for the first half of the year was approximately RMB 3.7 billion, up 60.9% year-on-year, with newly signed orders of approximately RMB 2.02 billion, up 98.0% year-on-year, of which 2Q26 newly signed orders amounted to approximately RMB 1.11 billion. Order performance continued to be impressive, further enhancing subsequent earnings visibility. Considering the positive recovery in domestic industry demand, combined with the company's continued overseas business expansion, the medium- to long-term growth potential of the company's business is favored. The company's A-shares and H-shares both maintain a "Buy" rating.